Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2017 09:00 ET | Source: Cortice Biosciences

Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer’s Disease and Related Tauopathies

– Possible evidence of clinical activity in Alzheimer’s disease patients treated with TPI 287 – – Drug administration was generally well-tolerated – – Results support further exploration of TPI 287...
June 05, 2017 09:00 ET | Source: Cortice Biosciences

Cortice Biosciences Announces Presentation of Final Results from the Dose Escalation Stage of a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma

– 13.4 month median overall survival; 64% of patients alive after one year – – 60% objective response rate; 96% disease stabilization rate – – Clinical outcomes and biomarker data...
May 18, 2017 09:00 ET | Source: Cortice Biosciences

Cortice Biosciences Announces an Upcoming Presentation at the 2017 American Society of Clinical Oncology Annual Meeting

NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that final results from the dose-escalation portion of a Phase 1/2 clinical trial evaluating TPI 287 for treatment of...
November 18, 2016 09:00 ET | Source: Cortice Biosciences

Cortice Biosciences Announces Presentation of Results from a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma at the 21st Annual Scientific Meeting of the Society of Neuro-Oncology

– Median overall survival improved to 13.4 from 12.9 months after extended follow-up – – 64% of patients alive after one year compared to historical rates of 25-38% – –...
June 03, 2016 10:06 ET | Source: Cortice Biosciences

Cortice Biosciences Announces Presentation of Results from a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma at the Annual Meeting of the American Society of Clinical Oncology

– 60% overall response rate; 96% achieved stable disease or better – – 12.9 mo. median and 60% 1-year overall survival in combination with Avastin® – – Safety profile remains...
November 20, 2015 09:45 ET | Source: Cortice Biosciences

Cortice Biosciences Announces Updated Results From Clinical Trials Evaluating TPI 287 for Treatment of Brain Malignancies

– 60% overall response rate; 12.9 month median and 71% 12-month overall survival in combination with Avastin® for treatment of recurrent glioblastoma – – Complete response and stable disease...
November 09, 2015 10:41 ET | Source: Cortice Biosciences

Cortice Biosciences Announces Upcoming Presentations at the 20th Annual Society for Neuro-Oncology Annual Scientific Meeting and Education Day

NEW YORK, Nov. 09, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that results from on-going clinical trials evaluating TPI 287 for treatment of brain cancers will be presented at the...
July 08, 2015 10:00 ET | Source: Cortice Biosciences

Cortice Biosciences Announces Issuance of a Key Patent Covering the Company's Alzheimer's Disease Drug Development Program

NEW YORK, July 08, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that Patent No. 9,072,746, “Method for Enhancing Learning and Memory Impaired by Neurodegenerative Disorders and...
May 26, 2015 10:11 ET | Source: Cortice Biosciences

Cortice Biosciences to Present at Upcoming Conferences

NEW YORK, May 26, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences, a clinical-stage drug development company pioneering novel therapies for oncologic and neurologic disease indications with urgent...
April 21, 2015 09:26 ET | Source: Cortice Biosciences

Cortice Biosciences Announces Updated Results From a Phase 1/2 Clinical Trial Evaluating TPI 287 for Treatment of Recurrent Glioblastoma

– 56% objective response rate in 16 evaluable patients treated with TPI 287 plus Avastin® – – Overall survival results maturing: median 12.6 months; 73% alive at 9 months, 67% alive at...